* Abcellera Biologics Inc ABCL.OQ ABCL.O is expected
to show a
fall in quarterly revenue when it reports results on February
20 for the period ending December 31 2023
* The Vancouver British Columbia-based company is expected
to
report a 58.8% decrease in revenue to $8.885 million from $21.55
million a year ago, according to the mean estimate from 10
analysts, based on LSEG data. (Majority is on Total revenue
basis)
* LSEG's mean analyst estimate for Abcellera Biologics Inc
is for
a loss of 13 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Abcellera
Biologics Inc is $19.00, above its last closing price
of $5.28.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.12 -0.13 -0.10 Beat 25.6
Jun. 30 2023 -0.11 -0.13 -0.11 Beat 15.4
Mar. 31 2023 -0.12 -0.14 -0.14 Met -3.2
Dec. 31 2022 0.00 -0.01 -0.10 Missed -1,804
.8
Sep. 0.05 0.05 0.08 Beat 76.1
30 2022
Jun. 30 2022 -0.01 -0.02 -0.02 Met -28.5
Mar. 31 2022 0.40 0.38 0.54 Beat 40.6
Dec. 31 2021 0.18 0.19 0.19 Met 0.6
This summary was machine generated February 16 at 22:57 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)